Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3944504

Cl[Pt]Cl.N.N#Cc1ccc(CO)cc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.48
CYP2A6 P11509 2/20 0.48
CYP11B1 P15538 3/20 0.46
CYP11B2 P19099 3/20 0.46
CYP19A1 P11511 4/20 0.44
IDO1 P14902 2/20 0.43
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA6 P23280 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
SAE1 Q9UBE0 1/20 0.41
UBA2 Q9UBT2 1/20 0.41
HTT P42858 1/20 0.41
KCNJ1 P48048 1/20 0.40
KCNH2 Q12809 1/20 0.40
CTBP2 P56545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92970 0.89 LOXL2 (0.58) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
Hydrogen Sulfide SCHEMBL27473257 0.87 LOXL2 (0.56) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL27707919 0.87 LOXL2 (0.56) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL12807987 0.83 MMP3 (0.58) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL31591073 0.83 SAE1 (0.56) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL3236728 0.83 MMP3 (0.58) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
Phosphoric Acid SCHEMBL28852152 0.79 LOXL2 (0.48) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL3178059 0.78 MAOB (0.59) LOXL2CYP2A6CYP11B1CYP11B2IDO1
SCHEMBL3233441 0.78 LTA4H (0.59) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL17253336 0.78 CYP1B1 (0.47) LOXL2CYP2A6CYP11B1CYP11B2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896492-B1 PLATINUM COMPLEXES WITH MONONITRILE-CONTAINING LIGANDS BIONUMERIK PHARMACEUTICALS INC (US) 2014-03-19 EP claimed
EP-1896492-B1 PLATINUM COMPLEXES WITH MONONITRILE-CONTAINING LIGANDS BIONUMERIK PHARMACEUTICALS INC (US) 2014-03-19 EP disclosed
US-7569606-B2 Platinum complexes with mononitrile-containing ligands BIONUMERIK PHARMACEUTICALS, INC. (US) 2009-08-04 US disclosed
US-20070173485-A1 Amminecyclohexanecarbonitriledichloroplatinum; platinum is capable of rapidly undergoing chelation with the Guanine or Adenine base of a DNA oligonucleotide at the 7 position; readily taken up by tumor cells JUNIPER NETWORKS, INC. 2007-07-26 US disclosed
US-7238823-B2 Platinum complexes with mononitrile-containing ligands BIONUMERIK PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
US-20070004798-A1 Platinum complexes with mononitrile-containing ligands BIONUMERIK PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004798-A1 Platinum complexes with mononitrile-containing ligands LIG4, RNMT, LIG1 LOXL2 3787/4885CYP2A6 3192/4885CYP11B1 3517/4885
US-20070173485-A1 Amminecyclohexanecarbonitriledichloroplatinum; platinum is capable of rapidly undergoing chelation with the Guanine or Adenine base of a DNA oligonucleotide at the 7 position; readily taken up by tumor cells RNMT, NSUN2, NUDT1 LOXL2 3229/4885CYP2A6 3216/4885CYP11B1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.